243 related articles for article (PubMed ID: 25743259)
21. The significance of non correlation between interleukin-8 serum levels with bone marrow microvascular density in patients with myeloma multiple.
Pappa CA; Tsirakis G; Boula A; Sfiridaki A; Psarakis FE; Alexandrakis MG; Stathopoulos EN
Pathol Oncol Res; 2013 Jul; 19(3):539-43. PubMed ID: 23456515
[TBL] [Abstract][Full Text] [Related]
22. Significance of Proliferation Markers and Prognostic Factors in Egyptian Patients with Multiple Myeloma.
Abdelgawad IA; Radwan NH; Shafik RE; Shokralla HA
Asian Pac J Cancer Prev; 2016; 17(3):1351-5. PubMed ID: 27039771
[TBL] [Abstract][Full Text] [Related]
23. The Impact of Mast Cell Density on the Progression of Bone Disease in Multiple Myeloma Patients.
Vyzoukaki R; Tsirakis G; Pappa CA; Devetzoglou M; Tzardi M; Alexandrakis MG
Int Arch Allergy Immunol; 2015; 168(4):263-8. PubMed ID: 26894886
[TBL] [Abstract][Full Text] [Related]
24. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.
Tsirakis G; Pappa CA; Kaparou M; Boula A; Katsomitrou V; Xekalou A; Kyriakaki S; Alexandrakis MG
Tumour Biol; 2013 Apr; 34(2):859-64. PubMed ID: 23242610
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
26. Angiogenic markers in plasma cell myeloma patients treated with novel agents.
Medinger M; Halter J; Heim D; Buser A; Gerull S; Stern M; Passweg J
Anticancer Res; 2015 Feb; 35(2):1085-90. PubMed ID: 25667497
[TBL] [Abstract][Full Text] [Related]
27. The Low Expression of IL-37 Involved in Multiple Myeloma - Associated Angiogenesis.
Li ZC; Sun MD; Zheng YQ; Fu HJ
Med Sci Monit; 2016 Nov; 22():4164-4168. PubMed ID: 27807338
[TBL] [Abstract][Full Text] [Related]
28. Increased serum levels of MIP-1alpha correlate with bone disease and angiogenic cytokines in patients with multiple myeloma.
Tsirakis G; Roussou P; Pappa CA; Kolovou A; Vasilokonstantaki C; Miminas I; Kyriakaki S; Alegakis A; Alexandrakis MG
Med Oncol; 2014 Jan; 31(1):778. PubMed ID: 24277416
[TBL] [Abstract][Full Text] [Related]
29. Positive correlation between bone marrow mast cell density and ISS prognostic index in patients with multiple myeloma.
Pappa CA; Tsirakis G; Roussou P; Xekalou A; Goulidaki N; Konsolas I; Alexandrakis MG; Stathopoulos EN
Leuk Res; 2013 Dec; 37(12):1628-31. PubMed ID: 24183234
[TBL] [Abstract][Full Text] [Related]
30. Notch1 overexpression promotes cell growth and tumor angiogenesis in myeloma.
Guo D; Li C; Teng Q; Sun Z; Li Y; Zhang C
Neoplasma; 2013; 60(1):33-40. PubMed ID: 23067214
[TBL] [Abstract][Full Text] [Related]
31. Serum concentrations and clinical significance of soluble CD40 ligand in patients with multiple myeloma.
Tsirakis G; Pappa CA; Psarakis FE; Fragioudaki M; Tsioutis C; Stavroulaki E; Boula A; Alexandrakis MG
Med Oncol; 2012 Dec; 29(4):2396-401. PubMed ID: 22403003
[TBL] [Abstract][Full Text] [Related]
32. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
33. [Link between osteoclastogenesis, angiogenesis and myeloma expansion].
Abe M
Clin Calcium; 2008 Apr; 18(4):473-9. PubMed ID: 18379029
[TBL] [Abstract][Full Text] [Related]
34. Angiogenesis in multiple myeloma.
Rajkumar SV; Kyle RA
Semin Oncol; 2001 Dec; 28(6):560-4. PubMed ID: 11740809
[TBL] [Abstract][Full Text] [Related]
35. Angiogenesis in multiple myeloma.
Jakob C; Sterz J; Zavrski I; Heider U; Kleeberg L; Fleissner C; Kaiser M; Sezer O
Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
[TBL] [Abstract][Full Text] [Related]
36. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
[TBL] [Abstract][Full Text] [Related]
37. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
[TBL] [Abstract][Full Text] [Related]
38. Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma.
Tsirakis G; Pappa CA; Kanellou P; Stratinaki MA; Xekalou A; Psarakis FE; Sakellaris G; Alegakis A; Stathopoulos EN; Alexandrakis MG
Hematol Oncol; 2012 Sep; 30(3):131-6. PubMed ID: 21919032
[TBL] [Abstract][Full Text] [Related]
39. Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade.
Xu JL; Lai R; Kinoshita T; Nakashima N; Nagasaka T
J Clin Pathol; 2002 Jul; 55(7):530-4. PubMed ID: 12101201
[TBL] [Abstract][Full Text] [Related]
40. Expression of proliferating cell nuclear antigen (PCNA) in multiple myeloma: its relationship to bone marrow microvessel density and other factors of disease activity.
Alexandrakis MG; Passam FH; Pappa CA; Dambaki C; Sfakiotaki G; Alegakis AK; Kyriakou DS; Stathopoulos E
Int J Immunopathol Pharmacol; 2004; 17(1):49-56. PubMed ID: 15000866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
